Our analysis of the difference in the efficacy of chemoimmunotherapy between women and men was similar to a previous meta-analysis which showed that women with advanced lung cancer achieved more statistically significant survival improvement from PD-1/PD-L1 inhibitors plus chemotherapy than men (29). This evidence concerns the gene CD274 and lung carcinoma.